28th Mar 2025 08:48
Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Commences up to GBP330 million share buyback programme. Says this represents the remainder of the GBP500 million allocated to buybacks in 2025, announced as part of its 2024 results in February. It follows the completion of Haleon's off-market repurchase of 44.2 million shares from Pfizer Inc for approximately GBP170 million, announced in March. Says the first tranche is for an up to GBP200 million consideration, commencing immediately and to end no later than June 26 this year. Haleon expects the buyback scheme to enhance its earnings per share, with Goldman Sachs hired to carry out the purchase of shares. Read More
